During the past decade, Investigaciones Clinicas Tucuman conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 9 clinical trials were completed, i.e. on average, 90% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 7 clinical trials were completed. i.e. 175% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Investigaciones Clinicas Tucuman" #1 sponsor was "Boehringer Ingelheim" with 5 trials, followed by "Eli Lilly and Company" with 3 trials sponsored, "EMD Serono" with 2 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 2 trials sponsored and "Resverlogix Corp" with 2 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Investigaciones Clinicas Tucuman" #1 collaborator was "Eli Lilly and Company" with 4 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "ICON plc" with 1 trials as a collaborator, "Medidata Solutions" with 1 trials as a collaborator and "PPD" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Investigaciones Clinicas Tucuman" are "Diabetes Mellitus, Type 2" (3 trials), "Heart Failure" (3 trials), "Lupus Erythematosus, Systemic" (2 trials), "Systemic Lupus Erythematosus" (2 trials) and "Atrial Fibrillation" (1 trials). Many other conditions were trialed in "Investigaciones Clinicas Tucuman" in a lesser frequency.

Most popular intervention types in "Investigaciones Clinicas Tucuman" are "Drug" (13 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Atacicept 150 mg" (2 trials), "Empagliflozin" (2 trials), "Apabetalone" (1 trials) and "Aspirin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Investigaciones Clinicas Tucuman" are 13 trials for "All" genders.

Currently, there are NaN active trials in "Investigaciones Clinicas Tucuman". undefined are not yet recruiting, 3 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Investigaciones Clinicas Tucuman, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Investigaciones Clinicas Tucuman, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".

Investigaciones Clinicas Tucuman has several departments that took part in Clinical trials: "Fundación CORI para la Investigación y Prevención del Cáncer" - 3 trials